Capricor Therapeutics announced that the FDA has extended the PDUFA target action date for deramiocel to November 22, 2026, following the submission of additional Phase 3 HOPE-3 data and analyses supporting a refined proposed indication. Key Highlights 🧬 Deramiocel BLA: FDA review remains ongoing. 📅 New PDUFA Date: November 22, 2026. 📊 Additional Phase 3 HOPE-3 data and analyses were submitted. 🎯 The additional data support a refined proposed indication. 🔎 The FDA extension provides additional time to review the submitted information. Why It Matters The November PDUFA decision remains a major catalyst for #CAPR, as FDA approval of deramiocel could significantly advance Capricor's commercial prospects. Explore more stock market insights and analysis on ThinkSabio. 🚀 Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/ ThinkSabio — Stocks Simplified